Cargando…
Clinical heterogeneity in patients with myoclonus associated to COVID-19
OBJECTIVE: This study aims to report the clinical heterogeneity of myoclonus in 6 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: Patient data were obtained from medical records from the University Hospital Dr. Josep Trueta, Girona, Spain. RESULTS: Six p...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731181/ https://www.ncbi.nlm.nih.gov/pubmed/34988717 http://dx.doi.org/10.1007/s10072-021-05802-1 |
_version_ | 1784627302566461440 |
---|---|
author | Álvarez Bravo, Gary Sánchez Cirera, Laura Angerri Nadal, Mònica Ramió i Torrentà, Lluís |
author_facet | Álvarez Bravo, Gary Sánchez Cirera, Laura Angerri Nadal, Mònica Ramió i Torrentà, Lluís |
author_sort | Álvarez Bravo, Gary |
collection | PubMed |
description | OBJECTIVE: This study aims to report the clinical heterogeneity of myoclonus in 6 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: Patient data were obtained from medical records from the University Hospital Dr. Josep Trueta, Girona, Spain. RESULTS: Six patients (5 men and 1 woman, aged 60–76 years) presented with different myoclonus phenotypes. All of them had a medical history of hypertension and overweight. The latency of myoclonus appearance ranged from 1 to 129 days. The phenotype most observed was generalized myoclonus. Special phenotypes such as painful legs and moving toes syndrome with jerking feet, Lazarus sign-like, action myoclonus/ataxia syndrome, and segmental myoclonus secondary to myelitis have been described too. Levetiracetam and clonazepam were medications most used successfully. Two patients died for complications not related to myoclonus. CONCLUSIONS: Our 6 cases highlight the heterogeneity of the clinical spectrum of myoclonus associated to COVID-19 (MYaCO). MYaCO pathogenesis is suspected to be due to an immune-mediated para- or post-infectious phenomenon; nevertheless, further research is needed to elucidate this hypothesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-021-05802-1. |
format | Online Article Text |
id | pubmed-8731181 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-87311812022-01-06 Clinical heterogeneity in patients with myoclonus associated to COVID-19 Álvarez Bravo, Gary Sánchez Cirera, Laura Angerri Nadal, Mònica Ramió i Torrentà, Lluís Neurol Sci Covid-19 OBJECTIVE: This study aims to report the clinical heterogeneity of myoclonus in 6 patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). METHODS: Patient data were obtained from medical records from the University Hospital Dr. Josep Trueta, Girona, Spain. RESULTS: Six patients (5 men and 1 woman, aged 60–76 years) presented with different myoclonus phenotypes. All of them had a medical history of hypertension and overweight. The latency of myoclonus appearance ranged from 1 to 129 days. The phenotype most observed was generalized myoclonus. Special phenotypes such as painful legs and moving toes syndrome with jerking feet, Lazarus sign-like, action myoclonus/ataxia syndrome, and segmental myoclonus secondary to myelitis have been described too. Levetiracetam and clonazepam were medications most used successfully. Two patients died for complications not related to myoclonus. CONCLUSIONS: Our 6 cases highlight the heterogeneity of the clinical spectrum of myoclonus associated to COVID-19 (MYaCO). MYaCO pathogenesis is suspected to be due to an immune-mediated para- or post-infectious phenomenon; nevertheless, further research is needed to elucidate this hypothesis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10072-021-05802-1. Springer International Publishing 2022-01-06 2022 /pmc/articles/PMC8731181/ /pubmed/34988717 http://dx.doi.org/10.1007/s10072-021-05802-1 Text en © Fondazione Società Italiana di Neurologia 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Covid-19 Álvarez Bravo, Gary Sánchez Cirera, Laura Angerri Nadal, Mònica Ramió i Torrentà, Lluís Clinical heterogeneity in patients with myoclonus associated to COVID-19 |
title | Clinical heterogeneity in patients with myoclonus associated to COVID-19 |
title_full | Clinical heterogeneity in patients with myoclonus associated to COVID-19 |
title_fullStr | Clinical heterogeneity in patients with myoclonus associated to COVID-19 |
title_full_unstemmed | Clinical heterogeneity in patients with myoclonus associated to COVID-19 |
title_short | Clinical heterogeneity in patients with myoclonus associated to COVID-19 |
title_sort | clinical heterogeneity in patients with myoclonus associated to covid-19 |
topic | Covid-19 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8731181/ https://www.ncbi.nlm.nih.gov/pubmed/34988717 http://dx.doi.org/10.1007/s10072-021-05802-1 |
work_keys_str_mv | AT alvarezbravogary clinicalheterogeneityinpatientswithmyoclonusassociatedtocovid19 AT sanchezcireralaura clinicalheterogeneityinpatientswithmyoclonusassociatedtocovid19 AT angerrinadalmonica clinicalheterogeneityinpatientswithmyoclonusassociatedtocovid19 AT ramioitorrentalluis clinicalheterogeneityinpatientswithmyoclonusassociatedtocovid19 |